Almirall offers update on Eklira developments

Almirall has posted the latest developments in trials around its chronic obstructive pulmonary disease (COPD) therapy Eklira (aclidinium bromide).

The company has revealed that trials into the drug have yielded positive results and compared aclidinium twice daily (BID) vs tiotropium and placebo in patients with moderate to severe COPD.

Eklira, which is a novel, long-acting inhaled anticholinergic bronchodilator that is administered using a state-of-the-art multidose dry powder inhaler called Genuair, displayed positive outcomes in the latest round of clinical tests.

Two further trials are now set to take place into the drug.

Executive director of research and development at Almirall Per-Olof Andersson stated: “Both studies will investigate the effects of aclidinium bromide in patients with moderate to severe COPD using a BID dosing regimen.”

Last month, Almirall released its latest product on to the skincare market – Blastoactivia – which is a skin cell repair cream containing double A select centella asiatica.